From 1982 through 1989, 56 patients with Stage III epithelial carcinom
a of the ovary received intraperitoneal chromic phosphate following ch
emotherapy and second look (52 pts) or as the only postsurgical manage
ment (4 pts). Median follow-up was 48 months (range of 24 to 108 month
s). The 4 patients treated following primary surgery with P-32 without
chemotherapy had microscopic abdominal disease (3 pts) or complete re
duction of gross abdominal disease (1 pt), and their 5-year survival w
as 100%. Of the 52 patients treated with P-32 following PAC chemothera
py, 23 were pathologic negative, 15 had microscopic residual, and 14 h
ad gross residual at second look. The 5-year survival following second
look was 75% for negative, 48% for microscopic, and 32% for gross res
idual. There were 4 Grade 3 GI complications (7%). There were no compl
ications in the 38 patients who received the P-32 within 12 hr of surg
ery. The use of P-32 as an adjuvant for Stage I and II epithelial carc
inoma of ovary has been found to be effective in prior GOG trials. We
have expanded the selection criteria in patients with Stage III carcin
oma to include those who can be surgically reduced to microscopic resi
dual at primary surgery or second look following chemo reduction. Beca
use of multiple prognostic variables affecting survival in Stage III o
varian cancer, a randomized study with control arm would be necessary
to draw firm conclusions regarding the effectiveness of P-32. The 5-ye
ar survival in this group of patients compares favorably to published
reports. (C) 1994 Academic Press, Inc.